Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline
« back

SAN DIEGO, Aug. 15, 2016 /PRNewswire/ —┬áScintilla Pharmaceuticals, Inc. (“Scintilla”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. (“Semnur”). Scintilla’s lead program is resiniferatoxin (“RTX”) for the treatment of intractable cancer pain. READ MORE »